2[2]Park S,Lee DY,Won JY,et al.Extrahepatic collateral supply of hepatocellular carcinoma by the intercostal arteries[J].JVIR,2003,14(4):461-468.
3[3]Gokan T,Hashimoto T,Matsui S,et al.Helical CT demonstration of dilated right nferior phrenic arteries as extrahepatic collateral arteries of hepatocellular carcinomas[J].J Comput Assist Tomogr,2001,25(1):68-73.
4[5]Tajima T,Honda H,Kuroiwa T,et al.Pulmonary complications after hepatic artery chemoembolization or infusion via the inferior phrenic artery for primary liver cancer[J].JVIR,2002,13(9):893-900.
5Kussmaul WG Ⅲ, Buchbinder M, Whitlow PL, et al. Rapid arterial hemostasis and decreased access site complications after cardiac catheterization and angioplasty: results of a randomized trial of a novel hemostatic device. J Am Coll Cardiol, 1995, 25:1685-
6Eggebrecht H, Haude M, Woertgen U, et al. Systematic use of a collagen-based vascular closure device immediately after cardiac catheterization procedures in 1317 consecutive patients. Cathet Cardiovasc Intervent, 2002, 57: 486-495.
7Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the FANTASTIC study. Circulation,1998, 98:1597-1603.
8Leon MB, Baim DS, Popma J J, et al. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting. N Engl J Med, 1998, 339: 1665-1671.
9Omoigui NA, Califf RM, Pieper K, et al. Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-1). J Am Call Cardiol, 1995, 26(4): 922-930.
10Blankenship JC, Hellkamp AS, Aguirre FV, et al. Vascular access site complications after percutaneous coronary interventions with abciximab in the evaluation of c7E3 for the prevention of ischemic complications (EPIC trial). Am J Cardiol, 1998, 81: 36-40.
